Eli Lilly & annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eli Lilly & Revenue Growth & History (LLY)
Eli Lilly & reported $65.18B in revenue for fiscal 2025, an increase of 44.70% from the previous fiscal year.
View full Eli Lilly & company overviewEli Lilly & annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $65.18B | $20.14B | +44.70% |
| 2024 | 2024-12-31 | $45.04B | $10.92B | +32.00% |
| 2023 | 2023-12-31 | $34.12B | $5.58B | +19.56% |
| 2022 | 2022-12-31 | $28.54B | $223.0M | +0.79% |
| 2021 | 2021-12-31 | $28.32B | $3.78B | +15.40% |
| 2020 | 2020-12-31 | $24.54B | $2.22B | +9.95% |
| 2019 | 2019-12-31 | $22.32B | $826.2M | +3.84% |
| 2018 | 2018-12-31 | $21.49B | $1.52B | +7.61% |
| 2017 | 2017-12-31 | $19.97B | −$1.25B | −5.88% |
| 2016 | 2016-12-31 | $21.22B | $1.26B | +6.33% |
| 2015 | 2015-12-31 | $19.96B | $343.1M | +1.75% |
| 2014 | 2014-12-31 | $19.62B | −$3.50B | −15.13% |
| 2013 | 2013-12-31 | $23.11B | $509.7M | +2.25% |
| 2012 | 2012-12-31 | $22.60B | −$1.68B | −6.93% |
| 2011 | 2011-12-31 | $24.29B | $1.21B | +5.25% |
| 2010 | 2010-12-31 | $23.08B | $1.24B | +5.68% |
| 2009 | 2009-12-31 | $21.84B | $1.46B | +7.19% |
| 2008 | 2008-12-31 | $20.37B | $1.74B | +9.33% |
| 2007 | 2007-12-31 | $18.63B | — | — |
Eli Lilly & quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $22.97B | $7.42B | +47.67% |
| Q1 2026 | 2026-03-31 | $19.80B | $7.07B | +55.54% |
| Q4 2025 | 2025-12-31 | $19.29B | $5.76B | +42.55% |
| Q3 2025 | 2025-09-30 | $17.60B | $6.16B | +53.87% |
| Q2 2025 | 2025-06-30 | $15.56B | $4.26B | +37.65% |
| Q1 2025 | 2025-03-31 | $12.73B | $3.96B | +45.18% |
| Q4 2024 | 2024-12-31 | $13.53B | $4.18B | +44.69% |
| Q3 2024 | 2024-09-30 | $11.44B | $1.94B | +20.43% |
| Q2 2024 | 2024-06-30 | $11.30B | $2.99B | +35.98% |
| Q1 2024 | 2024-03-31 | $8.77B | $1.81B | +25.98% |
| Q4 2023 | 2023-12-31 | $9.35B | $2.05B | +28.10% |
| Q3 2023 | 2023-09-30 | $9.50B | $2.56B | +36.84% |
| Q2 2023 | 2023-06-30 | $8.31B | $1.82B | +28.11% |
| Q1 2023 | 2023-03-31 | $6.96B | −$850.0M | −10.88% |
| Q4 2022 | 2022-12-31 | $7.30B | −$698.1M | −8.73% |
| Q3 2022 | 2022-09-30 | $6.94B | $168.8M | +2.49% |
| Q2 2022 | 2022-06-30 | $6.49B | −$252.1M | −3.74% |
| Q1 2022 | 2022-03-31 | $7.81B | $1.00B | +14.76% |
| Q4 2021 | 2021-12-31 | $8.00B | $559.9M | +7.53% |
| Q3 2021 | 2021-09-30 | $6.77B | $1.03B | +17.98% |
| Q2 2021 | 2021-06-30 | $6.74B | $1.24B | +22.56% |
| Q1 2021 | 2021-03-31 | $6.81B | $945.8M | +16.14% |
| Q4 2020 | 2020-12-31 | $7.44B | $1.33B | +21.69% |
| Q3 2020 | 2020-09-30 | $5.74B | $264.0M | +4.82% |
| Q2 2020 | 2020-06-30 | $5.50B | −$137.3M | −2.44% |
| Q1 2020 | 2020-03-31 | $5.86B | $767.6M | +15.07% |
| Q4 2019 | 2019-12-31 | $6.11B | $476.4M | +8.45% |
| Q3 2019 | 2019-09-30 | $5.48B | $169.7M | +3.20% |
| Q2 2019 | 2019-06-30 | $5.64B | $51.7M | +0.93% |
| Q1 2019 | 2019-03-31 | $5.09B | $128.4M | +2.59% |
| Q4 2018 | 2018-12-31 | $5.64B | $2.37B | +72.76% |
| Q3 2018 | 2018-09-30 | $5.31B | −$351.1M | −6.21% |
| Q2 2018 | 2018-06-30 | $5.58B | −$239.3M | −4.11% |
| Q1 2018 | 2018-03-31 | $4.96B | −$264.5M | −5.06% |
| Q4 2017 | 2017-12-31 | $3.26B | −$2.50B | −43.35% |
| Q3 2017 | 2017-09-30 | $5.66B | $466.3M | +8.98% |
| Q2 2017 | 2017-06-30 | $5.82B | $419.5M | +7.76% |
| Q1 2017 | 2017-03-31 | $5.23B | $363.2M | +7.47% |
| Q4 2016 | 2016-12-31 | $5.76B | $384.9M | +7.16% |
| Q3 2016 | 2016-09-30 | $5.19B | $232.0M | +4.68% |
| Q2 2016 | 2016-06-30 | $5.40B | $426.1M | +8.56% |
| Q1 2016 | 2016-03-31 | $4.87B | $220.4M | +4.75% |
| Q4 2015 | 2015-12-31 | $5.38B | $254.3M | +4.97% |
| Q3 2015 | 2015-09-30 | $4.96B | $84.1M | +1.72% |
| Q2 2015 | 2015-06-30 | $4.98B | $43.1M | +0.87% |
| Q1 2015 | 2015-03-31 | $4.64B | −$38.4M | −0.82% |
| Q4 2014 | 2014-12-31 | $5.12B | −$687.5M | −11.84% |
| Q3 2014 | 2014-09-30 | $4.88B | −$897.0M | −15.54% |
| Q2 2014 | 2014-06-30 | $4.94B | −$994.1M | −16.76% |
| Q1 2014 | 2014-03-31 | $4.68B | −$918.9M | −16.40% |
| Q4 2013 | 2013-12-31 | $5.81B | −$148.5M | −2.49% |
| Q3 2013 | 2013-09-30 | $5.77B | $329.3M | +6.05% |
| Q2 2013 | 2013-06-30 | $5.93B | $329.0M | +5.87% |
| Q1 2013 | 2013-03-31 | $5.60B | $0 | 0.00% |
| Q4 2012 | 2012-12-31 | $5.96B | −$89.3M | −1.48% |
| Q3 2012 | 2012-09-30 | $5.44B | −$704.6M | −11.46% |
| Q2 2012 | 2012-06-30 | $5.60B | −$652.1M | −10.43% |
| Q1 2012 | 2012-03-31 | $5.60B | −$237.2M | −4.06% |
| Q4 2011 | 2011-12-31 | $6.05B | −$140.4M | −2.27% |
| Q3 2011 | 2011-09-30 | $6.15B | $493.1M | +8.72% |
| Q2 2011 | 2011-06-30 | $6.25B | $504.1M | +8.77% |
| Q1 2011 | 2011-03-31 | $5.84B | $353.7M | +6.45% |
| Q4 2010 | 2010-12-31 | $6.19B | $252.8M | +4.26% |
| Q3 2010 | 2010-09-30 | $5.65B | $92.8M | +1.67% |
| Q2 2010 | 2010-06-30 | $5.75B | $455.9M | +8.61% |
| Q1 2010 | 2010-03-31 | $5.49B | $438.5M | +8.69% |
| Q4 2009 | 2009-12-31 | $5.93B | — | — |
| Q3 2009 | 2009-09-30 | $5.56B | $352.5M | +6.77% |
| Q2 2009 | 2009-06-30 | $5.29B | $142.4M | +2.76% |
| Q1 2009 | 2009-03-31 | $5.05B | — | — |
| Q3 2008 | 2008-09-30 | $5.21B | — | — |
| Q2 2008 | 2008-06-30 | $5.15B | — | — |
Eli Lilly & revenue growth trends
Over the last five reported fiscal years, revenue grew from $24.54B to $65.18B, a compound annual growth rate of 21.58%. Eli Lilly &'s latest reported quarter, Q2 2026, generated $22.97B in revenue, an increase of 47.67% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Eli Lilly & source filings ↗Community posts
Lilly’s obesity combination improves weight loss but raises discontinuation rates
Lilly ($LLY) reported that its experimental EloraTZP combination produced average weight loss of up to 23.3% over 48 weeks in a 367-person study involving overweight or obese adults with type 2 diabetes. The highest-dose combination of elor ...
Lilly seeks eczema label update after hand-and-foot study meets endpoints
Lilly ($LLY) said EBGLYSS achieved clear or almost clear hands and feet in 53% of treated patients after 16 weeks, compared with 27% on placebo, in the randomized ADtouch study. The 221-patient trial included adults and adolescents with mod ...
Lilly wins US approval for once-weekly insulin Onswik
Eli Lilly ($LLY) received FDA approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, used alongside diet and exercise. The decision gives the company a less frequently administered alternative to daily basal ins ...
